Drug Trial Radar · NCT07905131
A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Jan 15, 2027
Primary completion
Jun 30, 2029
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- Daniel Nussbaum, M.D.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bristol-Myers Squibb
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, feasibility, and recommended dose of navlimetostat (BMS-986504) combined with mFOLFIRINOX before and after surgery in patients with localized pancreatic cancer with MTAP deletion.
Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
NavlimetostatDrug
Investigational, small molecule anticancer agent being developed for the treatment of malignancies with homozygous deletion of the MTAP gene.
mFOLFIRINOX Treatment RegimenDrug
Chemotherapy regimen composed of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse EventsTime frame: Up to 15 months
- Recommended phase 2 dose of navlimetostat, as measured by the number of participants who experience a dose limiting toxicity during the first cycle of the phase 1b portion of the studyTime frame: Dose limiting toxicities are assessed throughout the first 28 days on combination treatment.
- Feasibility of perioperative navlimetostat combined with mFOLFIRINOXTime frame: Measured from the start of study treatment with navlimetostat through 14 days after surgery.
- Severity of Adverse EventsTime frame: Up to 15 months
- Incidence of dose limiting toxicitiesTime frame: The first 28 days of combination treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Duke University
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.